AMENDMENT TO SECURED 8% CONVERTIBLE PROMISSORY NOTESSecured 8% Convertible Promissory Notes • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
Contract Type FiledApril 2nd, 2007 Company Industry JurisdictionTHIS AMENDMENT (this "Amendment") to Secured 8% Convertible Promissory Notes (the "Notes") is made as of March 21, 2007, by and between Calypte Biomedical Corporation, a Delaware corporation (the "Company"), and Morningtown Limited, a limited liability company established in Mauritius (the “Investor”). If there is any inconsistency between the terms of this Amendment and any other agreement referenced herein, the terms of this Amendment will govern.
AMENDMENT NO. 3 TO SECURED 8% CONVERTIBLE PROMISSORY NOTESSecured 8% Convertible Promissory Notes • December 10th, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
Contract Type FiledDecember 10th, 2007 Company Industry JurisdictionTHIS AMENDMENT NO. 3 (this "Amendment") to Secured 8% Convertible Promissory Notes, as amended by Amendment No. 2 to Secured 8% Convertible Promissory Notes dated July 3, 2007, and Amendment to Secured 8% Convertible Promissory Notes dated March 21, 2007 (each, a “Note,” and collectively, the "Notes"), is made as of December 3, 2007, by and between Calypte Biomedical Corporation, a Delaware corporation (the "Company"), and Marr Technologies BV, a limited liability company established in the Netherlands (the “Investor”). If there is any inconsistency between the terms of this Amendment and any other agreement referenced herein, the terms of this Amendment will govern.
AMENDMENT TO SECURED 8% CONVERTIBLE PROMISSORY NOTESSecured 8% Convertible Promissory Notes • April 2nd, 2007 • Calypte Biomedical Corp • Laboratory analytical instruments • Delaware
Contract Type FiledApril 2nd, 2007 Company Industry JurisdictionTHIS AMENDMENT (this "Amendment") to Secured 8% Convertible Promissory Notes (the "Notes") is made as of March 21, 2007, by and between Calypte Biomedical Corporation, a Delaware corporation (the "Company"), and SF Capital Partners Ltd. (the “Investor”). If there is any inconsistency between the terms of this Amendment and any other agreement referenced herein, the terms of this Amendment will govern.